AI4S 是我们相当关注的领域， AI4S 是 RL 范式下最具有前景的应用领域之一， 随着测序、蛋白质 预测等生命科学领域的技术栈的完善、快速下降的测序成本带来的数据量积累，AI4S 的 scaling law 也 即将出现。 目录 01 Flagship 的创立 02 寻找 AI4S 领域的 Waymo 03 投资布局 04 投资哲学 01. 编译：Alin 编辑：Siqi 创立于 1999 年的 Flagship Pioneering 在美国投资界是个特殊的存在，海外独角兽曾对 Flagship 进行过 系统性研究：和普通 VC 不同，作为一家生物医药领域的创新投资平台，Flaghsip 自创立以来已孵化约 100 家创新企业，涉及生物医药、信息科技、农业和能源等领域，从 2003 年算起，Flagship 已经有 25 家公司成功实现 IPO，另外 48 家公司通过收购或并购的形式继续发展业务。 本文基于 No Priors 与 Flagship CEO Noubar Afeyan 的对谈编译整理，Afeyan 详细分享了 Flagship 对 AI for Science 的理解。 用创始人 Nou ...

Core Insights - ProMIS Neurosciences Inc. is set to present preclinical data on computationally-derived vaccines targeting neurodegenerative diseases at the AAN Annual Meeting in April 2025 [1][2] Group 1: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapeutics and vaccines for neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) [9] - The company utilizes a proprietary computational discovery platform, ProMIS™, to identify Disease Specific Epitopes on misfolded proteins [9] - PMN310, the lead product candidate, is a humanized monoclonal antibody designed to selectively bind toxic soluble amyloid-beta oligomers, which are believed to be a primary cause of neurodegeneration in AD [7][8] Group 2: Research and Development - The preclinical studies demonstrated that immunization with a single conformational epitope, peptide 301, resulted in maximal reactivity against AD brain oligomers [4] - The company is exploring a novel approach to vaccine design that targets misfolded toxic proteins, aiming to induce a specific immune response against amyloid-beta oligomers for AD and pathogenic alpha-synuclein for MSA [2][5] - Results indicated that vaccination with conformational B cell epitopes produced high-affinity antibodies with selectivity for pathogenic alpha-synuclein, preserving normal protein function [6] Group 3: Upcoming Presentations - ProMIS Neurosciences will present two key studies at the AAN Annual Meeting: - The first study focuses on optimizing Alzheimer's vaccine configuration to target toxic amyloid-beta oligomers, presented by Dr. Johanne Kaplan on April 9, 2025 [3] - The second study discusses the rational design of a vaccine for synucleinopathies, presented by Dr. Johanne Kaplan on April 8, 2025 [5]

Core Insights - Vigil Neuroscience announced positive Phase 1 clinical trial data for VG-3927, a potential treatment for Alzheimer's Disease, and plans to initiate a Phase 2 trial in Q3 2025 [1][2] - The company is on track to report final analysis from the IGNITE Phase 2 clinical trial for iluzanebart in ALSP in Q2 2025 [1][2] Recent Developments - Positive Phase 1 data for VG-3927 supports its advancement as a Phase 2-ready oral small molecule TREM2 agonist, potentially offering a new therapy for Alzheimer's disease [2][4] - The IGNITE Phase 2 trial for iluzanebart is expected to provide critical data for a potential breakthrough therapy for ALSP [2][4] Financial Performance - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $97.8 million, down from $111.3 million as of September 30, 2024 [8][13] - Research and Development (R&D) expenses for Q4 2024 were $18.7 million, compared to $16.8 million in Q4 2023, driven by increased clinical activity [8][11] - General and Administrative (G&A) expenses decreased to $6.4 million in Q4 2024 from $7.1 million in Q4 2023, attributed to lower external professional service fees [8][11] Clinical Trial Details - The Phase 1 trial for VG-3927 included 115 participants, demonstrating a favorable safety profile and a robust dose-dependent reduction of sTREM2 in cerebral spinal fluid [4][8] - The company plans to present Phase 1 data at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Disease in April 2025 [4][8]

CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 37th Ann ...

Company Overview - Vigil Neuroscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring the function of microglia, the immune cells of the brain [3] - The company is developing precision-based therapies to improve the lives of patients and their families, utilizing modern neuroscience drug development tools across multiple therapeutic modalities [3] Lead Clinical Candidates - Vigil's lead clinical candidate, Iluzanebart, is a fully human monoclonal antibody agonist targeting TREM2, aimed at treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease [3] - The company is also developing VG-3927, a novel small molecule TREM2 agonist, with an initial focus on Alzheimer's disease (AD) [3] Upcoming Events - Management will participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on March 19, 2025, at 9:00 a.m. ET [1] - A live webcast of the event will be available, and an archived version will be accessible for approximately 90 days following the event [2]

Core Insights - Immunocore presented initial data from the multiple ascending dose (MAD) portion of its Phase 1/2 STRIVE trial for IMC-M113V, a functional cure candidate for HIV, at CROI 2025, indicating the treatment is well tolerated and shows potential for viral control after antiretroviral treatment interruption [1][2][3] Group 1: Trial Data and Results - The MAD trial included 16 participants living with HIV who were stable on antiretroviral therapy (ART), with doses evaluated at 60 mcg, 120 mcg, and 300 mcg over 12 weeks, followed by a treatment interruption for up to 12 weeks [4][10] - No serious adverse events or dose-limiting toxicities were reported, with mild cytokine release syndrome observed in five participants at the highest dose [5][6] - Among 15 evaluable participants, delayed viral rebound was noted in 0 of 5 at 60 mcg, 1 of 5 at 120 mcg, and 2 of 5 at 300 mcg, with the historical rate for such observations being 5% [7][8] Group 2: Mechanism and Objectives - IMC-M113V employs a T cell receptor that targets HIV-infected immune cells, aiming to eliminate CD4+ cells containing integrated HIV DNA [10] - The STRIVE trial's objectives include establishing safe dosing regimens alongside ART and quantifying antiviral activity, specifically post-treatment viral control [11][13] Group 3: Future Directions - The company is advancing its clinical candidates to achieve a functional cure for HIV and aims for sustained control of the virus after ART cessation without virological relapse [13][14] - Further data from the trial at higher doses is anticipated, contributing to broader efforts to enable individuals with HIV to maintain health without lifelong ART [3][12]

Core Viewpoint - Shares of Novo Nordisk A/S (NVO) have declined following disappointing phase 3 results for CagriSema, which was unexpected given the anticipated consensus shift in treatment approaches [2] Group 1: Company Performance - Novo Nordisk A/S reported underwhelming phase 3 results for its drug CagriSema, leading to a drop in its stock price [2] Group 2: Market Reaction - The market's reaction to the phase 3 results was surprising, indicating a potential disconnect between investor expectations and the actual outcomes [2]

Group 1 - Tevogen Bio, a clinical-stage specialty immunotherapy biotech company, is leveraging AI to enhance precision medicine and operational efficiencies [2][3][5] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to AI [5][6] - Tevogen Bio aims to make advanced therapies more accessible and affordable by combining proprietary datasets with generative AI models [3][5] Group 2 - The recent AI discussion panel featured industry leaders discussing the transformative impact of AI across finance, biotech, and legal sectors [2][4] - The event highlighted the importance of tailoring AI applications to address unique challenges within each industry [3][4] - Tevogen Bio's leadership emphasizes the need for disruptive business models to sustain medical innovation and ensure patient accessibility [5][6]

Core Viewpoint - Passage Bio, Inc. (PASG) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system tracks the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts, and is crucial for understanding a company's earnings outlook [1][4]. - Changes in earnings estimates are strongly correlated with near-term stock price movements, as institutional investors adjust their valuations based on these estimates [4][6]. Recent Performance and Projections - For the fiscal year ending December 2025, Passage Bio is expected to earn -$0.69 per share, representing a 35.5% change from the previous year's reported number [8]. - Over the past three months, the Zacks Consensus Estimate for Passage Bio has increased by 6.1%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Passage Bio to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Insights - Oncolytics Biotech Inc. reported strong efficacy signals for its lead candidate, pelareorep, in treating HR+/HER2- metastatic breast cancer, pancreatic cancer, and anal cancer, indicating potential for redefining treatment landscapes in these high-need areas [1][2][16] - The company has a cash position of $15.9 million, providing a runway through critical milestones into the third quarter of 2025 [1][11] - Management is focused on advancing pelareorep towards registration-enabling studies, with significant data supporting its efficacy in multiple cancer types [2][4][6] Clinical Development - The BRACELET-1 trial demonstrated robust improvements in progression-free survival (PFS) and overall survival (OS) for patients receiving pelareorep combined with paclitaxel compared to paclitaxel alone [4][6] - The GOBLET study showed a 33% objective response rate in anal cancer patients treated with pelareorep and atezolizumab, including a complete response lasting over 15 months [5][15] - Ongoing combination studies in pancreatic cancer have cleared safety milestones, allowing for continued enrollment in the GOBLET study [5][15] Financial Performance - For Q4 2024, the company reported a net loss of $8.0 million, compared to a net loss of $3.9 million in Q4 2023, with a basic and diluted loss per share of $0.10 [11][14] - Research and development expenses for Q4 2024 were $4.6 million, slightly down from $4.7 million in Q4 2023, primarily due to lower personnel-related expenses [11][14] - The total assets as of December 31, 2024, were $20.2 million, down from $38.8 million in 2023, reflecting the company's ongoing investment in clinical trials [12][14] Anticipated Milestones - In H1 2025, the company plans to finalize the protocol for an adaptive registration-enabling trial for pelareorep in first-line pancreatic ductal adenocarcinoma and submit it to the FDA [11][19] - In H2 2025, the first patient is expected to be enrolled in the registration-enabling study for pelareorep and paclitaxel in advanced or metastatic HR+/HER2- breast cancer [11][19] - Initial efficacy results from Cohort 5 of the GOBLET study are anticipated in H2 2025, investigating pelareorep combined with modified FOLFIRINOX in newly diagnosed metastatic pancreatic cancer [11][19]